Literature DB >> 12379870

Site-specific genomic integration produces therapeutic Factor IX levels in mice.

Eric C Olivares1, Roger P Hollis, Thomas W Chalberg, Leonard Meuse, Mark A Kay, Michele P Calos.   

Abstract

We used the integrase from phage phiC31 to integrate the human Factor IX (hFIX) gene permanently into specific sites in the mouse genome. A plasmid containing attB and an expression cassette for hFIX was delivered to the livers of mice by using high-pressure tail vein injection. When an integrase expression plasmid was co-injected, hFIX serum levels increased more than tenfold to approximately 4 microg/ml, similar to normal FIX levels, and remained stable throughout the more than eight months of the experiment. hFIX levels persisted after partial hepatectomy, suggesting genomic integration of the vector. Site-specific integration was proven by characterizing and quantifying genomic integration in the liver at the DNA level. Integration was documented at two pseudo-attP sites, native sequences with partial identity to attP, with one site highly predominant. This study demonstrates in vivo gene transfer in an animal by site-specific genomic integration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379870     DOI: 10.1038/nbt753

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  77 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.

Authors:  Christopher L Chavez; Annahita Keravala; Jacqueline N Chu; Alfonso P Farruggio; Vanessa E Cuéllar; Jan Voorberg; Michele P Calos
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 3.  Biomedical and agricultural applications of animal transgenesis.

Authors:  Alison J Thomson; Jim McWhir
Journal:  Mol Biotechnol       Date:  2004-07       Impact factor: 2.695

Review 4.  Recent developments and current status of gene therapy using viral vectors in the United Kingdom.

Authors:  Kate Relph; Kevin Harrington; Hardev Pandha
Journal:  BMJ       Date:  2004-10-09

5.  Kinetics and longevity of ΦC31 integrase in mouse liver and cultured cells.

Authors:  Christopher L Chavez; Annahita Keravala; Lauren E Woodard; Robert T Hillman; Timothy R Stowe; Jacqueline N Chu; Michele P Calos
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

6.  Site-specific gene integration in cultured silkworm cells mediated by phiC31 integrase.

Authors:  Gaku Nakayama; Yutaka Kawaguchi; Katsumi Koga; Takahiro Kusakabe
Journal:  Mol Genet Genomics       Date:  2005-12-07       Impact factor: 3.291

Review 7.  Gene therapy of metabolic diseases.

Authors:  Alain Fischer; Salima Hacein-Bey-Abina; Marina Cavazzana-Calvo
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

8.  Integrating DNA vectors for gene therapy.

Authors:  Perry B Hackett
Journal:  Mol Ther       Date:  2007-01       Impact factor: 11.454

9.  A capsid-modified helper-dependent adenovirus vector containing the beta-globin locus control region displays a nonrandom integration pattern and allows stable, erythroid-specific gene expression.

Authors:  Hongjie Wang; Dmitry M Shayakhmetov; Tobias Leege; Michael Harkey; Qiliang Li; Thalia Papayannopoulou; George Stamatoyannopolous; André Lieber
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.

Authors:  Susana Ortiz-Urda; Qun Lin; Cheryl L Green; Douglas R Keene; M Peter Marinkovich; Paul A Khavari
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.